ANDA 203125, held by Hikma Pharmaceuticals. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 203125 (Methylprednisolone Sodium Succinate), held by Hikma Pharmaceuticals, was first approved by FDA on Sep 26, 2022, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 26, 2022 | Original application | Approved | None posted |
| Methylprednisolone Sodium SuccinateEQ 40MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Methylprednisolone Sodium SuccinateEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Jun 11, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 19, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 26, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters